Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing significant insurance coverage disparities.

In the logistic regression model of the top 20 factors, significant associations for semaglutide initiation included being female (adjusted odds ratio, 2.30), using certain medication classes ...

Eckel, MD, professor of medicine, emeritus in the division of endocrinology, metabolism and diabetes ... of semaglutide (Wegovy, Novo Nordisk) on cardiovascular outcomes for adults with obesity ...

In a recent study published in the journal ... 2.4 mg semaglutide versus placebo on cardiovascular events in individuals with cardiovascular disease and overweight or obesity without diabetes.

Additionally, semaglutide has been linked to improved cardiovascular outcomes in individuals with obesity but without diabetes, indicating its potential to address multiple health concerns ...

For overweight or obese individuals without diabetes ... data from the SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity, which showed the cardiac ...

2023 Semaglutide Reduces Cardio Risk in Obesity Without Diabetes Anne Peters discusses recent data on semaglutide and cardiovascular outcomes in patients with preexisting cardiovascular disease ...

In a recent study published in the journal ... effects of semaglutide on weight and anthropometric outcomes, as well as ...

The result from the SUMMIT study helps Lilly close the gap with Novo Nordisk, whose GLP-1 agonist semaglutide is already approved to reduce the risk of serious cardiovascular conditions in people ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated ...